![Sarah Burns BA (Hons)](https://profiles-cardiff.imgix.net/attachments/4955?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Miss Sarah Burns
(hi/ei)
BA (Hons)
Rheolwr Treialon Clinigol
Cyhoeddiad
2022
- Freeman, S. D. et al. 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140(S1), pp. 532-533. (10.1182/blood-2022-162245)
2017
- Burnett, A. K. et al. 2017. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia 31(2), pp. 310-317. (10.1038/leu.2016.225)
2009
- Macbeth, F. R., Griffiths, G. O., Noble, S. I. R., Burns, S. and Maughan, T. S. 2009. Interim safety data on the FRAGMATIC trial: a randomised phase III clinical trial investigating the effect of FRAGMin® added to standard therapy in patients with lung cancer [Abstract]. Journal of Thoraric Oncology 4(9), pp. S5-S968. (10.1097/JTO.0b013e3181b9c77e)
- Griffiths, G. O., Burns, S., Noble, S. I. R., Macbeth, F. R., Cohen, D. and Maughan, T. S. 2009. Fragmatic: a randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC Cancer 9, pp. 355-363. (10.1186/1471-2407-9-355)
Erthyglau
- Freeman, S. D. et al. 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140(S1), pp. 532-533. (10.1182/blood-2022-162245)
- Burnett, A. K. et al. 2017. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia 31(2), pp. 310-317. (10.1038/leu.2016.225)
- Macbeth, F. R., Griffiths, G. O., Noble, S. I. R., Burns, S. and Maughan, T. S. 2009. Interim safety data on the FRAGMATIC trial: a randomised phase III clinical trial investigating the effect of FRAGMin® added to standard therapy in patients with lung cancer [Abstract]. Journal of Thoraric Oncology 4(9), pp. S5-S968. (10.1097/JTO.0b013e3181b9c77e)
- Griffiths, G. O., Burns, S., Noble, S. I. R., Macbeth, F. R., Cohen, D. and Maughan, T. S. 2009. Fragmatic: a randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer. BMC Cancer 9, pp. 355-363. (10.1186/1471-2407-9-355)
Themâu ymchwil
Arbenigeddau
- Treialon Canser